# Phase 2 Study of VGT-309 in Lung Cancer

> **NCT05400226** · PHASE2 · COMPLETED · sponsor: **Vergent Bioscience, Inc.** · enrollment: 40 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** VGT-309

## Key facts

- **NCT ID:** NCT05400226
- **Lead sponsor:** Vergent Bioscience, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-24
- **Primary completion:** 2023-06-24
- **Final completion:** 2023-12-15
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2024-10-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05400226

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05400226, "Phase 2 Study of VGT-309 in Lung Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05400226. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*